Strides Pharma Science Limited's Board of Directors approved significant changes to its composition and senior leadership, effective June 1, 2026, following a meeting held on May 18, 2026. These decisions, based on recommendations from the Nomination and Remuneration Committee, are part of the company's comprehensive succession planning framework aimed at strengthening executive management representation and promoting internal talent. The board meeting commenced at 12:30 hrs IST and concluded at 14:15 hrs IST.

Key Board and Management Changes

The following changes to the Board of Directors and senior leadership have been approved:

Elevation of Ramaraju PVS as Executive Director

Venkata Seetharama Raju Pakalapati, widely known as Ramaraju PVS or Ram, has been appointed as a whole-time director designated as Executive Director for a period of three years with effect from June 1, 2026, subject to shareholders' approval. Ramaraju has been part of the Strides group for over 18 years and brings more than two decades of experience in the pharmaceutical and healthcare industry. His leadership approach is characterised by strategic foresight, collaborative synergy, and an unwavering commitment to excellence. As Executive Director, he will be responsible for overseeing global technical operations and the strategic management of critical functions including Manufacturing, Supply Chain, Procurement, and new digital initiatives. Consequent to this elevation, Ramaraju is designated as Key Managerial Personnel (KMP) effective June 1, 2026, and will cease as Senior Management Personnel (SMP) with effect from end of business hours of May 31, 2026.

Aditya Arun Kumar Transitions to Non-Executive Role

Aditya Arun Kumar has been redesignated as Non-Executive Director (Non-Independent) of the company with effect from June 1, 2026, subject to shareholders' approval. Aditya tendered his resignation from the executive role on May 13, 2026, citing the promoters' stated intention to further professionalize the management of Strides. He holds a Bachelor's Degree in Biomedical Sciences from Newcastle University and a Master of Research in Biophysics from King's College, London, and has over 13 years of experience in the pharmaceutical industry. Aditya commenced his career with Strides as a Management Trainee and has since held multiple roles across Strides and the promoter Family Office. He played a significant role in expanding and strengthening the partnered and B2B business verticals, having led the B2B business since 2022. Consequently, Aditya will cease to hold office as Executive Director – Business Development and as KMP with effect from end of business hours of May 31, 2026.

Nandini Matiyani and Ariff Khan Nominated as SMP

Nandini Matiyani has been nominated as Senior Management Personnel effective June 1, 2026. She has been part of Strides since December 2025 and brings over two decades of experience in human resources. Prior to joining Strides, she held senior HR leadership roles at RateGain, Wipro, and OnMobile Global.

Ariff Khan, Executive VP – Manufacturing Operations, has been nominated as SMP effective June 1, 2026, consequent to Ramaraju PVS's elevation to the Board. Ariff has been associated with Strides since May 2024 and currently heads manufacturing operations across India. He holds a Master's degree in Pharmacy and brings over 26 years of experience in the pharmaceutical sector.

Updated Board and KMP Composition

Following these changes, the updated Board of Directors of Strides Pharma Science effective June 1, 2026 comprises the following members:

The updated KMP list effective June 1, 2026 includes Badree Komandur (Managing Director & Group CEO), Venkata Seetharama Raju Pakalapati (Executive Director), Vikesh Kumar (Group CFO), and Manjula Ramamurthy (Company Secretary & Compliance Officer).

Strides Pharma Science has reported its audited consolidated and standalone financial results for the financial year ended March 31, 2026, delivering strong growth across profitability and efficiency metrics. FY26 consolidated EBITDA stood at ₹9,253M, reflecting a 15.3% year-on-year increase, while EBITDA margin expanded 140 basis points to 19.00%. Operational PAT surged 50.3% YoY to ₹5,181M, with Operational EPS at ₹56.20. On a standalone basis, revenue from operations stood at ₹21,801.35M and profit after tax from continuing operations reached ₹1,836.35M for FY26. The Board recommended a final dividend of ₹5 per equity share for FY26.

FY26 and Q4 Consolidated Financial Highlights

The company's latest performance reflects broad-based growth across quarterly and full-year metrics. The following table presents the consolidated financial highlights:

Reported PAT = PAT from continuing operations; Operational PAT = Reported PAT excluding exceptional items and one-time income

Standalone Financial Performance

On a standalone basis, Strides Pharma reported revenue from operations of ₹21,801.35M for FY26, compared to ₹21,394.23M in FY25. Profit after tax from continuing operations stood at ₹1,836.35M for FY26, against ₹591.56M in the previous year. The standalone results for Q4 FY26 reflect revenue from operations of ₹6,057.35M and profit after tax from continuing operations of ₹163.53M. The following table summarises key standalone financial metrics:

The standalone balance sheet as at March 31, 2026 reflects total assets of ₹53,957.19M (vs. ₹50,309.45M as at March 31, 2025) and total equity of ₹32,835.18M (vs. ₹31,927.35M). Net cash flow generated from operating activities for FY26 stood at ₹2,778.45M, compared to ₹4,214.83M in FY25. The statutory auditor, B S R & Co. LLP, has issued an unmodified opinion on both the standalone and consolidated financial results for FY26.

Geographic Revenue Performance

The updated figures reveal a differentiated growth trajectory across Strides Pharma's key markets. While the US market remains the larger revenue contributor, ex-US markets demonstrated significantly stronger momentum on a year-over-year basis. The table below presents the geographic revenue breakdown:

The company also reported Net Debt at ₹14,365M, impacted by foreign exchange (₹) depreciation of ₹1,115M. Net Debt to EBITDA improved to 1.55x in FY26 from 1.9x in FY25, while RoCE increased to 15.80% from 14.90% over the same period.

Management Commentary

Badree Komandur, MD & Group CEO, commented on the performance: "Strides continued to deliver strong performance across profitability, efficiency, and growth metrics during FY26. This was primarily driven by the Ex-US markets, which recorded a growth of 21% YoY. Our continued focus on profitability drove gross margin expansion of 310bps YoY and EBITDA margin improvement of 140bps YoY to 19%. Operational PAT and EPS grew by 50% YoY, reflecting strong operating leverage. Our calibrated strategy in Ex-US markets is delivering results, with these markets outpacing overall company growth. The US business remained stable during the year, though impacted by a weaker flu season in the second half. Despite ongoing geopolitical uncertainties and a challenging external environment, we are committed to delivering to long term sustainable and profitable growth."

Dividend Announcement

The Board of Directors recommended a final dividend of ₹5 per equity share of ₹10 each, at the rate of 50%, for the financial year ended March 31, 2026, subject to shareholder approval at the ensuing Annual General Meeting. The proposed dividend is expected to result in a cash outflow of approximately ₹461M. The record date for determining eligible shareholders will be fixed and intimated in due course, with dividend payment to be made within 30 days of shareholder approval.